Molecular imaging biomarkers for cell-based immunotherapies

Mohammad Haris, Puneet Bagga, Hari Hariharan, Bevin McGettigan-Croce, Laura A. Johnson, Ravinder Reddy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients' prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells.

Original languageEnglish
Article number140
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 19 Jun 2017

Fingerprint

Molecular imaging
Molecular Imaging
Biomarkers
Immunotherapy
Chemotherapy
T-cells
Imaging techniques
Arsenals
Radiation
Neoplasms
Oncology
Immune system
Magnetic resonance
Metabolism
Surgery
Toxicity
Tumors
Screening
Therapeutics
T-Lymphocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Haris, M., Bagga, P., Hariharan, H., McGettigan-Croce, B., Johnson, L. A., & Reddy, R. (2017). Molecular imaging biomarkers for cell-based immunotherapies. Journal of Translational Medicine, 15(1), [140]. https://doi.org/10.1186/s12967-017-1240-6

Molecular imaging biomarkers for cell-based immunotherapies. / Haris, Mohammad; Bagga, Puneet; Hariharan, Hari; McGettigan-Croce, Bevin; Johnson, Laura A.; Reddy, Ravinder.

In: Journal of Translational Medicine, Vol. 15, No. 1, 140, 19.06.2017.

Research output: Contribution to journalReview article

Haris, M, Bagga, P, Hariharan, H, McGettigan-Croce, B, Johnson, LA & Reddy, R 2017, 'Molecular imaging biomarkers for cell-based immunotherapies', Journal of Translational Medicine, vol. 15, no. 1, 140. https://doi.org/10.1186/s12967-017-1240-6
Haris, Mohammad ; Bagga, Puneet ; Hariharan, Hari ; McGettigan-Croce, Bevin ; Johnson, Laura A. ; Reddy, Ravinder. / Molecular imaging biomarkers for cell-based immunotherapies. In: Journal of Translational Medicine. 2017 ; Vol. 15, No. 1.
@article{bf70e817aa494c309b687ec56c08aa23,
title = "Molecular imaging biomarkers for cell-based immunotherapies",
abstract = "While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients' prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells.",
author = "Mohammad Haris and Puneet Bagga and Hari Hariharan and Bevin McGettigan-Croce and Johnson, {Laura A.} and Ravinder Reddy",
year = "2017",
month = "6",
day = "19",
doi = "10.1186/s12967-017-1240-6",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Molecular imaging biomarkers for cell-based immunotherapies

AU - Haris, Mohammad

AU - Bagga, Puneet

AU - Hariharan, Hari

AU - McGettigan-Croce, Bevin

AU - Johnson, Laura A.

AU - Reddy, Ravinder

PY - 2017/6/19

Y1 - 2017/6/19

N2 - While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients' prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells.

AB - While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients' prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells.

UR - http://www.scopus.com/inward/record.url?scp=85020935507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020935507&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1240-6

DO - 10.1186/s12967-017-1240-6

M3 - Review article

C2 - 28629457

AN - SCOPUS:85020935507

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 140

ER -